Table 2.
PK parameters of selected protein therapeutics approved by FDA.
| Brand Name | Generic Name | M. Wt. (kDa) | Half-life | CL | Vss | F | Route | Category |
|---|---|---|---|---|---|---|---|---|
| Mylotarg® | Gemtuzumab Ozogamicin | ~150 | 67 h | 0.353 L/h | 20.6 L | - | IV | ADC |
| Kadcyla® | Trastuzumab emtansine | ~150 | 4.2 d | 0.68 L/d | 60 mL/kg | - | IV | ADC |
| Adcetris® | Brentuximab vedotin | ~150 | 4–6 d | 1.5–1.8 L/d | 6–10 L | - | IV | ADC |
| Bexxar® | Tositumomab | ~150 | 67 h | - | - | - | IV | RIC |
| Zevalin® | Ibritumomab tiuxetan | ~150 | 30 h | - | - | - | IV | RIC |
| Removab® | Catumaxomab | ~150 | 2.13 d | - | - | 0.82 | IP | Bi-specific |
| Blincyto® | Blinatumomab | ~54 | 2.11 h | 2.92 L/h | 4.52 L | - | IV | Bi-specific |
| Kalbitor® | Ecallantide | ~7 | 2 h | 153 mL/min | 26.4 L | 0.91 | SC | Scaffold |
| Eylea®/Zaltrap® | (Ziv)-Aflibercept | ~97 | 5–6 d | 0.88 L/d | 4 L | - | IV, IVT | Fc-fusion |
| Enbrel® | Etanercept | ~150 | 70 h | 0.11 L/h | 10.4 L | 0.76 | SC | Fc-fusion |
| Arcalyst® | Rilonacept | ~251 | 7.7 d | 0.8 L/d | 9.36 L | 0.5 | SC | Fc-fusion |
| Eloctate® | Antihemophilic-Fc Fusion | ~220 | 19.7 h | 2.06 mL/h/kg | 49.5 mL/kg | - | IV | Fc-fusion |
| Alprolix® | Factor IX-Fc Fusion Protein | ~98 | 86.5 h | 3.3 mL/h/kg | 327 mL/kg | - | IV | Fc-fusion |
| Ontak® | Denileukin Diftitox | ~58 | 70–80 m | 0.6–2 mL/min/kg | 0.06–0.09 L/kg | - | IV | Immunotoxin |